What is Elastrin Therapeutics?
Elastrin Therapeutics is a South Carolina-based biotechnology firm dedicated to reversing cardiovascular disease through the restoration of elastin. Leveraging two decades of foundational research from Clemson University, the company has developed a sophisticated platform that targets and removes harmful calcification within arterial walls. By combining advanced particle design with precise elastin targeting, the firm aims to enhance drug efficacy while simultaneously mitigating the systemic side effects often associated with traditional cardiovascular treatments. This technology represents a paradigm shift in how clinicians approach the structural integrity of the vascular system.
How much funding has Elastrin Therapeutics raised?
Elastrin Therapeutics has raised a total of $12.5M across 2 funding rounds:
Angel/Seed
$2.5M
Unspecified
$10M
Angel/Seed (2021): $2.5M with participation from Kizoo
Unspecified (2022): $10M led by Kizoo
Key Investors in Elastrin Therapeutics
Kizoo
Kizoo is an investment firm focused on groundbreaking technologies in the fields of rejuvenation biotech and Internet & SaaS. The company aims to extend healthy lifespans through innovative therapies that address the aging process and its related diseases.
What's next for Elastrin Therapeutics?
With the recent infusion of capital, Elastrin Therapeutics is poised to accelerate its transition from laboratory-scale innovation to clinical-stage development. The strategic focus will likely center on optimizing its delivery mechanisms and expanding its pipeline of therapeutic candidates. As the company continues to refine its elastin-targeting platform, the primary objective will be to demonstrate safety and efficacy in human trials, a critical milestone for any biotech firm operating in the cardiovascular space. Investors are closely monitoring the company's ability to translate its proprietary research into scalable, market-ready medical solutions that address the root causes of age-related arterial stiffening.
See full Elastrin Therapeutics company page
